It hasn't captured nearly as much attention as Human Genome Sciences and its troubled launch of Benlysta in lupus, but XenoPort (XNPT) too has seen some serious disappointment with the launch of its drug Horizant. While XenoPort's lead drugs are unlikely to ever live up to initial hopes and legal wrangling with its partner Glaxo (GSK) will suck away precious cash, these shares may have been beaten down to a point of value.
Horizant - Efficacy Not The Issue; Cost-Benefit Is
Central to the XenoPort story today is the thus far disappointing launch of Horizant - the company's gabapentin prodrug for restless leg. While XenoPort and its partner Glaxo were able to navigate the shoals of the FDA approval process, approval and commercial launch has not been the key to easy money.
Read the full piece here:
Xenoport More Interesting After Washed Out Expectations
No comments:
Post a Comment